Clinical Trial

OCT-Angiography and Adaptive Optics in Patients With Memory Impairment

Study acronym: OCTAVO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 29, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI : amnestic mild cognitive impairment), or to other neurodegenerative diseases such as frontotemporal dementia or Lewy body diseases. These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and adaptive optics (AO) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying NCD. No study to date has studied the retina and its vessels in NCD using adaptive optics. In this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between patients with NCD and controls without NCD (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of NCD.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-05-14; most recent amendment 2025-09-26.
Status change: Not Yet Recruiting → Recruiting 2020-07-07
Trial Details
NCT Number NCT04389437
Lead Sponsor Fondation Ophtalmologique Adolphe de Rothschild
Conditions Amnesia, Alzheimer Disease, Lewy Body Disease, Parkinsons Disease With Dementia
Enrollment 450 participants
Start Date 2020-06-26
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-29